Phreesia acquires health tech company MediFind to enhance patient care

TAGS

Phreesia, a company engaged in patient intake, outreach, and activation, has announced the acquisition of , a health technology company, that utilizes advanced analytics to aid patients, particularly those with severe, chronic, and rare diseases, in obtaining superior care swiftly.

MediFind employs machine learning and proprietary algorithms to routinely assess medical information across extensive datasets. This process determines the leading doctors in specific conditions and fields based on criteria such as their research output, patient volume, and peer reputation. MediFind classifies these doctors into four levels of expertise: elite, distinguished, advanced, and experienced, with elite-level doctors being global leaders in their respective fields.

See also  Safflower Oil : Preparation, Properties, Standards, Synonyms, Chemical Constituents and Uses

MediFind’s CEO , who is now Vice President of Product Management at , founded the company following his brother’s diagnosis with a rare . Howie shared his pride in MediFind’s ability to identify leading doctors in their fields, expressing his enthusiasm for the opportunity to reach a larger audience through Phreesia’s extensive network.

See also  Sanofi to acquire Bioverativ for $11.6bn to expand into rare blood disorders

Phreesia’s Senior Vice President, David Linetsky, highlighted the alignment between Phreesia’s mission and MediFind’s focus. He stated, “At Phreesia, we’re always thinking about how to arm patients with the right tools and relevant information,” He welcomed MediFind colleagues to join in addressing these challenges collaboratively.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This